Please assess the completion status of the following clinical trial:

Trial Title: Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Pediatric:~Inclusion Criteria:~* 5-17 years of age~* diagnosed with GERD or any other stomach acid mediated condition for which a PPI treatment is provided~* currently under a Proton Pump Inhibitor (PPI) therapy or will start a PPI therapy~* Parents/legal guardians and or child must have access to internet and a valid email address~Exclusion Criteria:~* history of extensive esophageal or gastric surgery~* diagnosed with any major chronic illness or conditions that in the opinion of the gastroenterologist that would interfere with participation in the study~* history of Phenylketonuria (PKU) and patients with a history of previous adverse effects from PPI treatment or sensitivity to aspartame (NutraSweet, Equal)~Adult:~Inclusion Criteria:~* 18 years of age or older~* Gastroesophageal Reflux Disease symptoms~* Being initiated on PPI therapy OR continues to have symptoms despite PPI therapy~Exclusion Criteria:~* Extensive esophageal or gastric surgery~* Any chronic illness that would interfere with the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Adult Genotype guided treatment (Type: EXPERIMENTAL): For adults randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
- Adult Conventional treatment (Type: NO_INTERVENTION): For adults randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
- Pediatric Genotype guided treatment (Type: EXPERIMENTAL): For children randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
- Pediatric Conventional treatment (Type: NO_INTERVENTION): For children randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).